Barrel Eye announced on the 23rd that its artificial intelligence (AI)-based breast tumor diagnostic support software "Vis-BUS" has received approval as a Class III medical device from the Ministry of Food and Drug Safety.
Barrel Eye is a research startup founded in 2021 by Professor Bae Hyun-min of the Korea Advanced Institute of Science and Technology (KAIST), utilizing AI technology to research and develop quantitative ultrasound diagnostic equipment.
Breast cancer is one of the cancers for which early detection is crucial for successful treatment, making accurate and rapid diagnosis essential. Traditionally, ultrasound imaging has tended to rely on the experience and judgment of specialists skilled in interpretation. However, Barrel Eye's Vis-BUS allows for objective diagnosis by quantitatively analyzing whether a tumor is benign or malignant through AI.
Barrel Eye emphasized that Vis-BUS will play a key role in alleviating the burden on medical staff and minimizing diagnostic errors.
A Barrel Eye representative noted, "Vis-BUS is highly compatible with existing ultrasound equipment, allowing for easy adoption in small hospitals and screening centers, and it will provide opportunities to utilize cutting-edge AI diagnostic technology even in areas or hospitals with limited medical resources."